Regulation & Compliance

Heineken’s new smartband at Coachella uses music data to spark friendships, blending tech and sociability while raising questions about data privacy.

A new partnership promises to help banks deploy AI for fraud and compliance in weeks, tackling legacy systems and rising regulatory pressure.

Coro's new AI integration lets users manage security via ChatGPT, but this leap in convenience comes with a new frontier of potential security risks.

The Christopher Street Project’s massive rally on the National Mall united thousands to demand action and directly engage lawmakers on trans rights.

Kekst CNC appoints 20-year veteran Lyndsey Estin as Co-CEO, signaling a strategic focus on AI and cybersecurity in a major leadership shift.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

PMGC Holdings touts major acquisitions and a promising biotech pipeline, but a look at its financials reveals a high-stakes bet on future growth.

Analyses reveal the EPA allows pesticides with high cancer risks on the market without warning labels, raising major public health and legal questions.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

The Diocese of Albany agrees to a $148 million settlement for 440 abuse claims, a major step in its bankruptcy and a victory for survivor advocates.

Amidst record staff shortages, FranklinCovey claims its trust-based leadership model can heal the healthcare system, one hospital team at a time.

New data reveals a slight drop in Tennessee's youth suicide rates, yet the crisis persists as a leading cause of death, sparking urgent calls for action.

Canada's $4T investment sector warns new investor protection rules are too costly, sparking a debate on market safety versus industry competitiveness.

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

Indian tech firm Lexlegis launches its Legal AID platform in the U.S., promising a new 'Legal Intelligence Factory' free from AI errors.

Ontario's nurses praise new primary and home care funds but warn that cuts to harm reduction and inaction on social issues create a dangerous public health gap.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

The company aims to slash production costs by 50% with AI, while deploying a powerful open-source agent that brings both promise and significant risk.

Trooly.AI's new platform uses AI agents to conduct 45-minute user interviews, but its 'Empathy Engine' raises new questions about tech and ethics.

EnerSys will unveil its strategic framework and technology roadmap, outlining its plan to navigate the energy transition and capitalize on market growth.